Loading...
Market
What will be the clinical trial outcome for Genentech's RGT-4198 CDK inhibitor by December 31, 2025?
2
Resolution / Starting Odds
Complete Response (CR) • 25%
Partial Response (PR) • 25%
Stable Disease (SD) • 25%
Progressive Disease (PD) • 25%
Clinical trial results and Genentech's official announcements
Story
Genentech Acquires Regor's CDK Inhibitors in Definitive Purchase Agreement for $850M
Sep 30, 2024, 11:05 AM
Genentech has announced the acquisition of Regor's portfolio of next-generation CDK inhibitors for $850 million upfront, with potential additional milestone payments. This acquisition includes CDK inhibitors such as RGT-4198, which is in phase 1 and targets CDK4/2/6 with some CDK9 activity. The deal is part of a Definitive Purchase Agreement and is expected to enhance Genentech's oncology pipeline, particularly in the treatment of breast cancer. Roche, the parent company of Genentech, is also projecting more than 3 billion Swiss francs ($3.6 billion) in peak sales from its drug candidates in obesity and diabetes, acquired from Carmot Therapeutics.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Breast cancer • 25%
Lung cancer • 25%
Colorectal cancer • 25%
Other cancer types • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
Decrease or no change • 25%
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Yes • 50%
No • 50%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial extended • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
